eumycetoma

DEFINITION of eumycetoma

Eumycetoma is a chronic, granulomatous, subcutaneous mycosis caused by true filamentous fungi — most commonly Madurella mycetomatis — that enters through a penetrating skin injury, proliferates in subcutaneous tissue, and progressively destroys muscle, bone, joint, and tendon over months to decades if untreated. It presents as the clinical triad of a painless, indurated subcutaneous swelling; multiple draining sinus tracts discharging to the skin surface; and grains (compact fungal colonies, typically black or white depending on the causative species) visible in the discharge — a triad that is pathognomonic for mycetoma as a class. Eumycetoma is distinguished from its close mimicker actinomycetoma — the bacterial form of mycetoma caused by filamentous aerobic bacteria such as Nocardia brasiliensis — by both etiology and treatment: actinomycetoma responds to prolonged antibiotics, whereas eumycetoma requires prolonged antifungal therapy (typically itraconazole for 9-12 months) combined with surgical debridement, with amputation reserved for advanced cases; coding the correct type (B47.0 vs. B47.1) is therefore clinically and therapeutically critical. The underlying pathological mechanism involves fungal hyphae aggregating into compact grains surrounded by a fibrous capsule that severely limits drug penetration, creating a chronic granulomatous inflammatory response composed of neutrophils, epithelioid histiocytes, and giant cells — with the characteristic Splendore-Hoeppli phenomenon (eosinophilic material radiating from the grain surface) visible on histopathology. Eumycetoma affects the foot in approximately 80% of cases — hence the historical eponym “Madura foot” — though the hand, leg, and trunk can also be involved. The disease is endemic in Sub-Saharan Africa (especially Sudan), India, parts of South America, and Mexico, and was designated a neglected tropical disease by the WHO in 2016; in US coding practice it is rare but encountered in immigrant populations and returning travelers, making specificity at coding time especially important for public health surveillance.

---

ETYMOLOGY of eumycetoma

greek

Component	Origin	Meaning
eu-	Greek εὖ (eu, yoo), adverb/prefix	”true,” “real,” “well,” “good” — in taxonomic/medical contexts, eu- is used as a prefix meaning “true” or “typical,” distinguishing the genuine form from a lookalike (e.g., eumycetoma = true fungal mycetoma, as opposed to actinomycetoma)
myc- / myket-	Greek μύκης (mýkēs, MY-kays), genitive μύκητος (mýkētos)	“fungus,” “mushroom” — the primary combining form for fungal organisms and fungal disease throughout medical terminology
-oma	Greek -ωμα (-ōma, OH-mah), noun-forming suffix from -o- + -ma	Noun-forming suffix — “mass,” “tumor,” “swelling” — indicates a pathological mass or growth; in this word it denotes the tumor-like granulomatous swelling

The compound eumycetoma was coined in the late 19th to early 20th century in New Latin medical taxonomy, built entirely from Greek components: eu- (“true”) + mykētos (genitive of mýkēs, “fungus”) + -oma (“mass”) — literally “true fungal mass.” It was formulated to distinguish the purely fungal form of mycetoma from the bacterially caused form once microbiological methods could separate the two etiologies. The foundational root myc-/myket- (“fungus”) generates the entire myc- root family in medicine: mycosis (fungus + condition → any fungal disease), mycology (fungus + study of → science of fungi), onychomycosis (nail + fungus + condition → fungal nail infection), dermatomycosis (skin + fungus + condition → superficial fungal skin infection), and actinomycosis (ray + fungus + condition → disease caused by filamentous bacteria originally mistaken for fungi). The prefix eu- functions as a taxonomic distinguishing prefix in medicine: compare eukaryote (true nucleus), eubacteria (true bacteria), and euthyroid (true/normal thyroid function).

---

🔀 ALIASES / ALTERNATE TERMS

• Eumycotic mycetoma (full scientific descriptor; used interchangeably in pathology and infectious disease literature to emphasize the fungal [eumycotic] etiology; coded B47.0)
• Madura foot, mycotic / Maduromycosis (historical eponym from the Madura district of India where the disease was first described in the 19th century; both included as official ICD-10-CM “includes” notes under B47.0; “mycotic” qualifier differentiates it from actinomycotic Madura foot)
• Fungal mycetoma (lay and clinical synonym; most accessible term for patient education and non-specialist documentation)
• Black grain mycetoma (descriptive clinical subtype — black grains on discharge indicate organisms such as Madurella mycetomatis, Falciformispora senegalensis, Curvularia lunata, or Exophiala jeanselmei; all coded B47.0)
• White grain mycetoma (descriptive clinical subtype — white or pale grains suggest Scedosporium boydii (formerly Pseudallescheria boydii), Acremonium spp., or Fusarium spp.; coded B47.0)
• Actinomycetoma (the bacterial mimic of eumycetoma; caused by aerobic filamentous bacteria — Nocardia brasiliensis, Streptomyces somaliensis, Actinomadura madurae; clinically identical presentation but responds to antibiotics; coded B47.1 — never code B47.0 when documentation specifies bacterial/actinomycotic etiology)
• Mycetoma, unspecified (when etiology — fungal vs. bacterial — cannot be determined or is not documented; coded B47.9 — avoid on inpatient profee if grain color or culture/histopathology data is available to support specificity)

---

🔗 RELATED TERMS

• Actinomycetoma — the bacterial form of mycetoma; clinically indistinguishable from eumycetoma on examination alone but caused by filamentous aerobic bacteria rather than true fungi; treated with antibiotics (e.g., dapsone + streptomycin); coded B47.1; the most critical differential to establish before initiating treatment
• Mycetoma — the umbrella clinical syndrome encompassing both eumycetoma and actinomycetoma; defined by the classic triad of subcutaneous swelling, draining sinuses, and grain discharge; coded B47.9 when etiology is unspecified
• Madurella mycetomatis — the most common causative fungal agent of eumycetoma worldwide; produces characteristic black grains; demonstrates the fibrous capsule that limits antifungal drug penetration
• Grain (mycetoma) — compact colony of the causative organism embedded in a polysaccharide-protein matrix; the hallmark microbiological finding; grain color (black vs. white/pale) is a key diagnostic discriminator for identifying likely causative species and guiding antifungal selection
• Splendore-Hoeppli phenomenon — the eosinophilic hyaline material radiating from the fungal grain surface on H&E staining; a classic histopathologic finding in eumycetoma and other fungal/parasitic infections; its presence on histopathology is a prompt for the provider to specify the diagnosis in documentation
• Chromoblastomycosis — another chronic subcutaneous fungal infection; shares the deep tissue tropism and geographic overlap with eumycetoma but is characterized by verrucous skin lesions and muriform (sclerotic) cells on histopathology rather than grains and sinuses; coded B43.0-B43.9
• Sporotrichosis — another subcutaneous mycosis in the differential; presents with nodular lymphangitic spread rather than sinus formation; coded B42.0-B42.9
• Itraconazole — the first-line antifungal agent for eumycetoma; given for 9-12 months at 400 mg/day; limited by low bioavailability into fibrosed tissue and relatively poor cure rates (~26%) when used alone
• Fosravuconazole — investigational antifungal (a prodrug of ravuconazole) with improved tissue penetration currently under clinical investigation by the Drugs for Neglected Diseases initiative (DNDi) as a more effective treatment for eumycetoma
• Debridement — the primary surgical intervention for eumycetoma; involves wide excision or serial debridement of infected soft tissue, muscle, fascia, and bone; always combined with antifungal therapy to reduce recurrence
• Histopathology — the definitive diagnostic method for eumycetoma; deep biopsy with H&E staining and special stains (GMS, PAS) identifies fungal hyphae within grains, grain morphology, and the surrounding granulomatous reaction
• Neglected tropical disease (NTD) — WHO-designated category of diseases that primarily affect low-income populations in tropical/subtropical regions; eumycetoma was added to the WHO NTD list in 2016, driving increased funding for research and treatment access

---

CODING CORNER

🏥 ICD-10-CM CODES

Mycetoma — Primary Etiologic Category (B47)

Code	Description
B47	Mycetoma — parent/header code, NOT billable
B47.0	Eumycetoma — includes: Madura foot, mycotic; Maduromycosis (fungal/true fungal etiology confirmed by culture, histopathology, or grain characteristics)
B47.1	Actinomycetoma (bacterial etiology — Nocardia, Streptomyces, Actinomadura spp.; coded separately from eumycetoma; requires different treatment)
B47.9	Mycetoma, unspecified — Madura foot NOS (use ONLY when etiology — fungal vs. bacterial — is truly undetermined; avoid when culture or histopathology results are available)

Complication Codes — Bone Involvement

Code	Description
M86.9	Osteomyelitis, unspecified (sequence as additional code when eumycetoma extends to bone, if not documented as a distinct fungal osteomyelitis; provider query recommended for specificity)
M89.50	Osteolysis, unspecified site (may apply when bone destruction is documented without frank osteomyelitis)

Associated Diagnostic Finding

Code	Description
R23.8	Other skin changes — may be used as an additional code for draining sinus or fistula at skin surface when not captured by the primary diagnosis code

Post-Procedural / Amputation Status

Code	Description
Z89.511	Acquired absence of right foot (amputation status — sequence after B47.0 when amputation was performed as treatment)
Z89.512	Acquired absence of left foot
Z89.611	Acquired absence of right leg below knee
Z89.612	Acquired absence of left leg below knee

---

🔧 COMMON CPT CODES (Eumycetoma Diagnosis & Surgical Management)

CPT Code	Description
87101	Culture, fungi (mold); skin, hair, or nail — primary microbiological test to identify causative fungal species and guide antifungal selection
87205	Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types — initial rapid stain on grain discharge
88305	Level IV — Surgical pathology, gross and microscopic examination; tissue biopsy (includes subcutaneous and deep soft tissue) — required for definitive histopathologic diagnosis and grain identification
11042	Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less — initial debridement session for superficial/subcutaneous eumycetoma
+11045	Debridement, subcutaneous tissue; each additional 20 sq cm, or part thereof — add-on code; list separately in addition to 11042
11043	Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); first 20 sq cm or less — used when infection extends into muscle/fascial planes
+11046	Debridement, muscle and/or fascia; each additional 20 sq cm, or part thereof — add-on to 11043
11044	Debridement, bone (includes epidermis, dermis, subcutaneous tissue, muscle and/or fascia, if performed); first 20 sq cm or less — used for advanced eumycetoma with bone involvement/osteolysis
+11047	Debridement, bone; each additional 20 sq cm, or part thereof — add-on to 11044
27880	Amputation, leg, through tibia and fibula — below-knee amputation; reserved for advanced cases not responsive to combined antifungal and surgical therapy
27882	Amputation, leg, through tibia and fibula; open, circular (guillotine) — staged open amputation technique

---

⚠️ Coding Note: On inpatient profee, B47.0 vs. B47.1 is not a distinction you should ever resolve by defaulting to B47.9 when diagnostic data exists in the record — histopathology, culture results, or even grain color documentation in the operative note (black grains = fungal → B47.0; white/yellow granules with filamentous bacteria on Gram stain = bacterial → B47.1) are sufficient to support the specific code, and the treatment plan will reflect the correct etiology in almost every case. The single biggest undercoding trap on eumycetoma claims is failure to additionally capture bone involvement — if operative notes, imaging (MRI or plain film), or pathology describe bone destruction, erosion, or cortical involvement, this warrants a query to support a secondary osteomyelitis or osteolysis code alongside B47.0, as it significantly affects the clinical picture and DRG weight. For CPT debridement code selection, depth drives the code — 11042 (subcutaneous), 11043 (muscle/fascia), 11044 (bone) — and when multiple tissue layers are debrided in the same session, you report only the deepest layer code (e.g., 11044 + +11047 when bone is reached, NOT all three depth codes stacked); this is a common audit failure point. Add-on codes +11045, +11046, and +11047 require the parent code to be present and are not reported alone. For eumycetoma in a US inpatient context, because it is a rare/exotic diagnosis, expect medical necessity documentation requirements and possible prior authorization challenges for prolonged antifungal infusion therapy — modifier -22 may be applicable for significantly more extensive debridement than typical for the procedure, but requires detailed operative note documentation to survive audit.

---

DERIVATIONS of eumycetoma

TABLE definition AS Definition
FROM #medterm 
WHERE length(filter(roots, (word) => econtains([[eumycetoma]].roots, word))) > 0 AND file.name != [[eumycetoma]].file.name
SORT file.name ASC

---

Query functionality

TABLE definition AS Definition
FROM #medterm 
WHERE length(filter(definition, (word) => econtains([[eumycetoma]].definition, word))) > 0 AND file.name != [[eumycetoma]].file.name

Med roots Appendix A Prefixes Appendix B Combining Forms Appendix C Suffixes Appendix D Suffix forms